Revista medica del Instituto Mexicano del Seguro Social · 2019
[Acetylsalicylic acid in prevention of pre-eclampsia].
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Godínez Víctor, Godínez-Vázquez Víctor Junior, Godínez-Vázquez Paulina Del Rocío, Sosa-Bustamante Gloria Patricia, Díaz de León-Morales Luz Verónica
Аннотация
BACKGROUND: Pre-eclampsia (PE) is an important cause of morbidity and mortality in our country.
OBJECTIVE: Evaluate if the administration of acetylsalicylic acid (ASA) at a low dose reduces its presence.
METHODS: Comparative, cohort study. Pregnant women with risk factors for PE: Primigravidae, PE antecedent and twin pregnancy were included. Primigravidae and multigested with previous vascular pathology weren't included. Group 1: 150, 11 excluded, 80 mg ASA from week 20 at the end of pregnancy. Group 2: 150, without ASA. The presence of PE or gestational hypertension (HG) was monitored. General data and clinical controls were taken. Chi square and relative risk (RR) were calculated.
RESULTS: Group 1: n = 139, 26 ± 5.6 years, 9% PE. Group 2: n = 150, 25.5 ± 5.6 years, PE 20% (p = 0.01), RR 0.47 (95% CI 0.19 - 0.87) (p = 0.01), attributable risk -0.11 equivalent to an absolute reduction of 11% for PE in group 1.
CONCLUSIONS: Pregnant women with risk factor for PE who received ASA diminished the risk of developing PE in 50%.
OBJECTIVE: Evaluate if the administration of acetylsalicylic acid (ASA) at a low dose reduces its presence.
METHODS: Comparative, cohort study. Pregnant women with risk factors for PE: Primigravidae, PE antecedent and twin pregnancy were included. Primigravidae and multigested with previous vascular pathology weren't included. Group 1: 150, 11 excluded, 80 mg ASA from week 20 at the end of pregnancy. Group 2: 150, without ASA. The presence of PE or gestational hypertension (HG) was monitored. General data and clinical controls were taken. Chi square and relative risk (RR) were calculated.
RESULTS: Group 1: n = 139, 26 ± 5.6 years, 9% PE. Group 2: n = 150, 25.5 ± 5.6 years, PE 20% (p = 0.01), RR 0.47 (95% CI 0.19 - 0.87) (p = 0.01), attributable risk -0.11 equivalent to an absolute reduction of 11% for PE in group 1.
CONCLUSIONS: Pregnant women with risk factor for PE who received ASA diminished the risk of developing PE in 50%.